Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 12;13(2):100103.
doi: 10.1016/j.waojou.2020.100103. eCollection 2020 Feb.

Adherence to omalizumab: A multicenter "real-world" study

Raffaele Campisi  1 , Claudia Crimi  1 , Rossella Intravaia  2 , Simona Strano  2 , Alberto Noto  3 , Maria Pia Foschino  4 , Giuseppe Valenti  5 , Vittorio Viviano  5 , Corrado Pelaia  6 , Luisa Ricciardi  7 , Nicola Scichilone  8 , Nunzio Crimi  2
Affiliations

Adherence to omalizumab: A multicenter "real-world" study

Raffaele Campisi et al. World Allergy Organ J. .

Abstract

Background: Adherence to medications is crucial in patients with severe asthma in light of the negative clinical impact and costs of non-adherence. Adherence to omalizumab has not been well studied in real-world settings. The aim of this study was to assess adherence to omalizumab and evaluate treatment effectiveness in relation to adherence.

Methods: This was a retrospective, observational, and multicenter real-world study. Omalizumab dose, timing of administration, and duration of treatment (<2 years; 2-4 years; > 4 years) were analyzed. Adherence was evaluated by examining rates of expected and missing doses. Good adherence (<10% of doses missed) and poor adherence (>10% doses missed) were determined. For effectiveness in relation to adherence of omalizumab we considered asthma exacerbations, hospitalizations, asthma control test (ACT), and Forced Expiratory Volume in 1 s (FEV1).

Results: A total of 196 patients were evaluated, and 161 were suitable for data analyses. Good adherence was shown in 90.7% of patients and poor adherence in 9.3%. Considering adherence in relation to treatment duration: <2 years, 87.8% of patients were adherent (expected doses, 1186; missed doses, 53); 2-4 years, 85.9% were adherent (expected doses, 2985; missed doses, 127); >4 years, 100% were adherent (expected doses, 6120; missed doses, none). Indices of efficacy between pre- and post-treatment showed significant improvement (p < 0.001). The effectiveness indices between pre- and post-treatment, among adherent and non-adherent patients, ACT, and asthma exacerbations both showed significant differences (p = 0.043 and p = 0.049, respectively). Binomial logistic regression analysis showed that increasing age, better ACT score, and 14-day timing were significantly associated with increased adherence to therapy.

Conclusions: High adherence to omalizumab was demonstrated in a real-world setting, which was associated with better outcomes and control of asthma.

Keywords: Adherence; Efficacy; Omalizumab; Real-world; Severe asthma.

PubMed Disclaimer

Conflict of interest statement

All the authors declare no competing interests.

References

    1. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497. - PubMed
    1. Caminati M., Senna G., Stefanizzi G. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience. BMC Pulm Med. 2016;16:128. - PMC - PubMed
    1. World Health Organization (WHO). Adherence to long-term therapies: evidence for action. Dis specific Rev. http://www.who.int/chp/knowledge/publications/adherence_section3.pdf. Accessed June 18, 2013.
    1. Bender B.G., Bender S.E. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin. 2005;25:107–130. - PubMed
    1. Broder M.S., Chang E.Y., Ory C. Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care population. Allergy Asthma Proc. 2009;30:148–157. - PubMed

LinkOut - more resources